rss
BMJ Case Reports 2009; doi:10.1136/bcr.08.2008.0654
  • Reminder of important clinical lesson

Hydroxychloroquine: a diabetic drug in disguise?

  1. Lydia Kang1,
  2. Ted R Mikuls2,
  3. James R O’Dell2
  1. 1
    University of Nebraska Medical Center, General Internal Medicine, MSB 5544, 983331, Omaha, Nebraska, 68198-3331, USA
  2. 2
    University of Nebraska Medical Center, Rheumatology, 983025 Nebraska Medical Center, Omaha, Nebraska, 68198-3025, USA
  1. lkang{at}unmc.edu
  • Published 2 March 2009

Summary

Hydroxychloroquine (HCQ) is an antimalarial agent that is commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The present report documents a case of hypoglycaemia due to HCQ in a patient with SLE and diabetes mellitus type 2, in which the HCQ completely replaced the need for daily subcutaneous insulin.

Footnotes

  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.

This Article

  1. Summary
  2. Full text

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog